These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26141627)

  • 1. Demographic Studies from a National Gaucher Disease Screening Program.
    Gagnon DM; Pergament E; Fine BA
    J Genet Couns; 1998 Oct; 7(5):385-99. PubMed ID: 26141627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease in patients and obligate carriers of Gaucher disease.
    Becker JG; Pastores GM; Di Rocco A; Ferraris M; Graber JJ; Sathe S
    Parkinsonism Relat Disord; 2013 Jan; 19(1):129-31. PubMed ID: 22940477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular aspects of Gaucher disease in New Zealand.
    Woodfield MJ; Woodfield DG; Winship IM
    N Z Med J; 1997 Aug; 110(1050):316-9. PubMed ID: 9315031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
    Choy FY
    Am J Med Genet; 1985 Jul; 21(3):519-28. PubMed ID: 4025386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease.
    Sinclair GB; Jevon G; Colobong KE; Randall DR; Choy FY; Clarke LA
    Mol Genet Metab; 2007 Feb; 90(2):148-56. PubMed ID: 17079175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world.
    Sobreira E; Pires RF; Cizmarik M; Grabowski GA
    Mol Genet Metab; 2007 Jan; 90(1):81-6. PubMed ID: 16996765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
    Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
    Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
    J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 Gaucher disease with hydrops fetalis in an Ashkenazi Jewish family resulting from a novel recombinant allele and a rare splice junction mutation in the glucocerebrosidase locus.
    Reissner K; Tayebi N; Stubblefield BK; Koprivica V; Blitzer M; Holleran W; Cowan T; Almashanu S; Maddalena A; Karson EM; Sidransky E
    Mol Genet Metab; 1998 Apr; 63(4):281-8. PubMed ID: 9635296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a 55-bp deletion in the glucocerebrosidase gene in Gaucher disease: phenotypic presentation and implications for mutation detection assays.
    Mao R; O'Brien JF; Rao S; Schmitt E; Roa B; Feldman GL; Spence WC; Snow K
    Mol Genet Metab; 2001 Mar; 72(3):248-53. PubMed ID: 11243731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.
    Zuckerman S; Lahad A; Shmueli A; Zimran A; Peleg L; Orr-Urtreger A; Levy-Lahad E; Sagi M
    JAMA; 2007 Sep; 298(11):1281-90. PubMed ID: 17878420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal aspects of Gaucher disease: a review.
    Wenstrup RJ; Roca-Espiau M; Weinreb NJ; Bembi B
    Br J Radiol; 2002; 75 Suppl 1():A2-12. PubMed ID: 12036828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Enzyme replacement therapy for Gaucher disease introduced in late adulthood].
    Juhász P; Tóth B; Maródi L; Erdos M
    Orv Hetil; 2012 Feb; 153(7):264-70. PubMed ID: 22318527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and application to clinical practice of a validated HPLC method for the analysis of β-glucocerebrosidase in Gaucher disease.
    Colomer EG; Gómez MA; Alvarez AG; Martí MC; Moreno PL; Zarzoso MF; Jiménez-Torres NV
    J Pharm Biomed Anal; 2014 Mar; 91():123-30. PubMed ID: 24447963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaucher disease: from fundamental research to effective therapeutic interventions.
    de Fost M; Aerts JM; Hollak CE
    Neth J Med; 2003 Jan; 61(1):3-8. PubMed ID: 12688562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaucher disease: an overview of clinical characteristics and therapy.
    Kingma W
    J Intraven Nurs; 1996; 19(2):79-82. PubMed ID: 8852167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells.
    Siebert M; Westbroek W; Chen YC; Moaven N; Li Y; Velayati A; Saraiva-Pereira ML; Martin SE; Sidransky E
    RNA Biol; 2014; 11(10):1291-300. PubMed ID: 25584808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.